Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances.
liquid biopsies
miRNA and protein biomarkers
minimally-invasive biomarkers
urinary extracellular vesicles
urologic cancers
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
09
02
2021
revised:
08
03
2021
accepted:
17
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Urologic cancers are a heterogeneous group of tumors, some of which have poor prognosis. This is partly due to the unavailability of specific and sensitive diagnostic techniques and monitoring tests, ideally non- or minimally invasive. Hence, liquid biopsies are promising tools that have been gaining significant attention over the last decade. Among the different classes of biomarkers that can be isolated from biofluids, urinary extracellular vesicles (uEVs) are a promising low-invasive source of biomarkers, with the potential to improve cancer diagnosis and disease management. Different techniques have been developed to isolate and characterize the cargo of these vesicles; however, no consensus has been reached, challenging the comparison among studies. This results in a vast number of studies portraying an extensive list of uEV-derived candidate biomarkers for urologic cancers, with the potential to improve clinical outcome; however, without significant validation. Herein, we review the current published research on miRNA and protein-derived uEV for prostate, bladder and kidney cancers, focusing on different uEV isolation methods, and its implications for biomarker studies.
Identifiants
pubmed: 33810357
pii: cancers13071529
doi: 10.3390/cancers13071529
pmc: PMC8036842
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Instituto Português de Oncologia do Porto
ID : CI-IPOP-PI27-FB-GEBC
Organisme : Fundação para a Ciência e a Tecnologia
ID : POCI-01-0145-FEDER-030831
Organisme : Fundação para a Ciência e a Tecnologia
ID : PTDC/BTM-TEC/30831/2017
Organisme : Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona
ID : LCF/BQ/DR20/11790013
Références
J Extracell Vesicles. 2013 Dec 31;2:
pubmed: 24455109
ACS Nano. 2017 Nov 28;11(11):10712-10723
pubmed: 29090896
Eur Urol. 2017 Mar;71(3):437-446
pubmed: 28029399
Expert Rev Mol Diagn. 2019 May;19(5):367-375
pubmed: 30961397
Prostate. 2020 Feb;80(2):113-132
pubmed: 31825540
Sci Rep. 2018 Mar 2;8(1):3945
pubmed: 29500443
Biochim Biophys Acta Gen Subj. 2017 Jan;1861(1 Pt A):3164-3179
pubmed: 27495390
Pharmaceutics. 2018 Nov 06;10(4):
pubmed: 30404188
PLoS One. 2013 Sep 19;8(9):e74801
pubmed: 24069349
PLoS One. 2019 Apr 10;14(4):e0215003
pubmed: 30970027
Med Clin North Am. 2020 Nov;104(6):1051-1062
pubmed: 33099450
Oncol Lett. 2014 Oct;8(4):1701-1706
pubmed: 25202395
Am J Physiol Renal Physiol. 2007 May;292(5):F1657-61
pubmed: 17229675
Clin Biochem. 2013 Apr;46(6):456-65
pubmed: 23228867
Prostate. 2017 Jul;77(10):1167-1175
pubmed: 28617988
Clin Chem Lab Med. 2014 Mar;52(3):345-54
pubmed: 24101370
J Biotechnol. 2017 Oct 10;259:135-139
pubmed: 28764970
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Oncotarget. 2017 Apr 11;8(15):24668-24678
pubmed: 28160564
Prostate. 2017 May;77(6):573-583
pubmed: 27990656
Eur Urol. 2012 Jan;61(1):58-64
pubmed: 21840642
Indian J Urol. 2015 Oct-Dec;31(4):289-96
pubmed: 26604439
Cancer Res. 2019 Jul 1;79(13):3503-3513
pubmed: 31097475
Oncotarget. 2017 Jan 17;8(3):4960-4976
pubmed: 27903962
Magn Reson Imaging Clin N Am. 2014 May;22(2):135-44, v
pubmed: 24792674
Methods Mol Biol. 2017;1660:221-232
pubmed: 28828660
Eur Urol. 2016 Aug;70(2):323-31
pubmed: 26924769
Mol Cancer. 2017 Oct 5;16(1):156
pubmed: 28982366
Methods. 2012 Feb;56(2):293-304
pubmed: 22285593
Am Fam Physician. 2017 Oct 15;96(8):507-514
pubmed: 29094888
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Sci Rep. 2017 Apr 24;7:46224
pubmed: 28436447
Am J Transl Res. 2015 Nov 15;7(11):2500-9
pubmed: 26807194
Kidney Int. 2006 Apr;69(8):1471-6
pubmed: 16501490
Front Oncol. 2020 May 07;10:724
pubmed: 32457844
Oncotarget. 2017 Aug 8;8(53):91199-91208
pubmed: 29207636
J Extracell Vesicles. 2016 Jun 29;5:31209
pubmed: 27363484
Urol Clin North Am. 2003 Nov;30(4):843-52
pubmed: 14680319
Lab Chip. 2018 Oct 9;18(20):3144-3153
pubmed: 30191215
Curr Opin Urol. 2014 Sep;24(5):487-91
pubmed: 24887047
Kidney Int. 2010 Apr;77(8):736-42
pubmed: 20130532
Am J Physiol Renal Physiol. 2014 Jun 1;306(11):F1251-9
pubmed: 24694589
Kidney Int. 2014 Aug;86(2):433-44
pubmed: 24352158
Eur Urol. 2016 Apr;69(4):660-673
pubmed: 26323946
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
Oncotarget. 2015 Oct 6;6(30):30357-76
pubmed: 26196085
Int J Mol Med. 2019 Jan;43(1):83-90
pubmed: 30365060
PLoS One. 2013;8(1):e53016
pubmed: 23326375
Nat Methods. 2017 Feb 28;14(3):228-232
pubmed: 28245209
J Extracell Vesicles. 2016 Feb 15;5:29497
pubmed: 26895490
ACS Nano. 2017 Feb 28;11(2):1360-1370
pubmed: 28068467
Sci Rep. 2016 Sep 30;6:34446
pubmed: 27686150
World J Oncol. 2020 Jun;11(3):79-87
pubmed: 32494314
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Nat Rev Urol. 2020 Jan;17(1):11-27
pubmed: 31827264
J Circ Biomark. 2016 Mar 1;5:4
pubmed: 28936252
Oncotarget. 2016 Apr 19;7(16):22566-78
pubmed: 26992225
J Cell Mol Med. 2019 Oct;23(10):6755-6765
pubmed: 31342628
Int J Mol Sci. 2020 Nov 06;21(21):
pubmed: 33172003
Nat Biomed Eng. 2019 Jun;3(6):438-451
pubmed: 31123323
J Proteome Res. 2012 Dec 7;11(12):5611-29
pubmed: 23082778
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Mol Biosyst. 2013 Jun;9(6):1220-33
pubmed: 23511837
Nanomedicine. 2011 Dec;7(6):780-8
pubmed: 21601655
Nephrol Dial Transplant. 2008 Jun;23(6):1799-801
pubmed: 18310721
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
PLoS One. 2016 Jun 15;11(6):e0157566
pubmed: 27305142
Eur Urol. 2005 Sep;48(3):386-99; discussion 398-9
pubmed: 15982797
Proteomics. 2014 Mar;14(4-5):412-25
pubmed: 24339442
J Nanobiotechnology. 2019 Jul 18;17(1):85
pubmed: 31319859
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32485907
Cell Prolif. 2019 Nov;52(6):e12659
pubmed: 31469460
J Cancer Res Clin Oncol. 2019 Nov;145(11):2725-2736
pubmed: 31552489
Kidney Int. 2010 Oct;78(8):810-6
pubmed: 20686450
Anal Bioanal Chem. 2019 Aug;411(21):5351-5361
pubmed: 31267193
Eur J Pharm Sci. 2017 Feb 15;98:70-79
pubmed: 27751843
Nephrology (Carlton). 2017 Nov;22(11):854-863
pubmed: 27496221
Lab Chip. 2014 Oct 7;14(19):3773-80
pubmed: 25099143
Mol Cancer. 2015 Nov 14;14:194
pubmed: 26576778
J Proteome Res. 2008 May;7(5):2088-96
pubmed: 18373357
Eur Urol Focus. 2016 Jun;2(2):210-218
pubmed: 28723537
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Cancer Treat Res Commun. 2020;24:100195
pubmed: 32688293
J Extracell Vesicles. 2020 Mar 11;9(1):1736935
pubmed: 32284825
J Urol. 2013 Feb;189(2):422-9
pubmed: 23017522
J Extracell Vesicles. 2015 May 28;4:27369
pubmed: 26025625
Biosens Bioelectron. 2017 May 15;91:588-605
pubmed: 28088752
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
J Proteome Res. 2018 Aug 3;17(8):2572-2580
pubmed: 29905074
Mol Cells. 2018 Mar 31;41(3):179-187
pubmed: 29562735
Eur J Pharm Sci. 2017 Feb 15;98:80-85
pubmed: 27664330
Urology. 2014 Jun;83(6):1443.e9-15
pubmed: 24726313
Front Oncol. 2020 Oct 28;10:582843
pubmed: 33194717
Proteomics Clin Appl. 2010 Jan;4(1):84-96
pubmed: 21137018
Nat Rev Urol. 2017 Feb;14(2):90-97
pubmed: 27872478
Sci Rep. 2017 Feb 17;7:42961
pubmed: 28211531
Kidney Int. 2012 Nov;82(9):1024-32
pubmed: 22785172
Bioengineering (Basel). 2019 Jan 16;6(1):
pubmed: 30654439
Biomed Res Int. 2018 Jan 30;2018:8545347
pubmed: 29662902
Sci Rep. 2020 Apr 6;10(1):5960
pubmed: 32249794
Nat Rev Urol. 2014 Dec;11(12):688-701
pubmed: 25403245
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13368-73
pubmed: 15326289
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30
pubmed: 26733552
Lab Chip. 2014 Jun 7;14(11):1891-900
pubmed: 24722878